https://www.nationalreview.com/corner/the-long-sad-saga-of-hydroxychloroquine/
The same medical community which is telling us that HCQ is dangerous, may soon be telling us that a vaccine developed in record time is completely safe.
I want to make sure NR readers don’t miss this essay from Norman Doidge. It’s the best thing I’ve read on hydroxychloroquine. But beware: The piece is long and fascinating. Once you start reading, you won’t be able to stop, and it takes a good half hour to finish.
Doidge tells the tale of hydroxychloroquine, or HCQ as he calls it, as if the drug were a character in a story. His main point is that HCQ hasn’t received fair treatment in many quarters, including, unfortunately, some of the health experts advising the government of the United States. The main reasons are the intrusion of politics into medicine, the pitfalls and limitations of big data in medical science, and the over-reliance of many experts on random controlled testing to the exclusion of other kinds of evidence.
Doidge manages to make even a discussion of research methodology interesting. Here is a sample:
We now have studies that show one of the weaknesses of RCTs (random controlled testing) is that in the quest to eliminate confounding factors, they end up, in a majority of cases, excluding patients who are typical of those in the population. The RCT evangelist focuses only on the RCT strengths, and forgets their weaknesses. A typical RCT describes several data points about hundreds of patients. It can be helpful in determining what treatment might work for most people in a large population. A typical case history describes perhaps hundreds of data points about a single patient. Its focus might be on what treatment might work best for this patient. Sometimes we need all that information about a patient, to choose a proper treatment, because individual patients differ, often in decisive ways.